Akhet Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-06-2024
- Paid Up Capital ₹ 0.10 M
as on 21-06-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
as on 21-06-2024
- Revenue 107.68%
(FY 2022)
- Profit 375.49%
(FY 2022)
- Ebitda 1500.35%
(FY 2022)
- Net Worth 63.35%
(FY 2022)
- Total Assets 116.23%
(FY 2022)
About Akhet Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Nitin Gulati and Ravinder Gulati serve as directors at the Company.
- CIN/LLPIN
U24239HR2016PTC064665
- Company No.
064665
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Yamuna Nagar, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Akhet Pharmaceuticals Private Limited offer?
Akhet Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Common Disease Medicines, Antihistamines, Juices, Soups & Soft Drinks, Instant Drink Mix, Vitamin Tablets & Capsules, Mineral Supplement, Digestive System Drugs & Medicines, Gastrointestinal Drugs.
Who are the key members and board of directors at Akhet Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Gulati  | Director | 21-Jun-2016 | Current |
| Ravinder Gulati | Director | 21-Jun-2016 | Current |
Financial Performance of Akhet Pharmaceuticals.
Akhet Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 107.68% increase. The company also saw a substantial improvement in profitability, with a 375.49% increase in profit. The company's net worth Soared by an impressive increase of 63.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akhet Pharmaceuticals?
In 2021, Akhet Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 23 Dec 2021 | ₹0.50 M | Open |
How Many Employees Work at Akhet Pharmaceuticals?
Unlock and access historical data on people associated with Akhet Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akhet Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akhet Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
